Dong Seok Kim
CEO AevisBio Inc.
Dong Seok Kim is the founder of Aevis Bio, with extensice experience in both basic and transltaional research in relation to the ubiquitin-proteasome system in cancer biology and immunology. At Aevis Bio, his work focuses on the development of the Molecular Glue Degrader discovery platform to identify novel scaffolds applicable to multipel drug targets.
Seminars
Wednesday 28th January 2026
Redefining Parkinson’s Treatment with Dual-Action Molecular Glues
2:00 pm
- Dual actions on key pathogenic drivers – simultaneously degrading ZFP91 to suppress inflammation and blocking alpha-synuclein aggregation
- From neuroprotection to functional recovery – demonstrated broad beneficial effects in cognition and motor outcomes
- Validated across multiple models of neurodegeneration – robust and reproducible biological actions confirmed in vitro and in vivo
